Investors unimpressed by Almirall's modest sales guidance raise

9 November 2023
almirall_large

Spanish drugmaker Almirall (BME: ALM) left investors less than impressed with its latest financial results.

The Barcelona-based dermatology specialist was trading 4% lower on Thursday afternoon, following the presentation of the company’s figures from the first nine months of 2023.

"As we gear up for the lebrikizumab launch, we're embarking on a transformative journey for our company"Net sales for this period reached 674.6 million euros ($721.1 million), a rise of more than 6%, while total earnings before interest, taxes, depreciation and amortization (EBITDA) were 137.8 million euros, down 6% but in line with expectations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical